keyword
MENU ▼
Read by QxMD icon Read
search

stephen hanauer

keyword
https://www.readbyqxmd.com/read/28594651/mir-4728-3p-functions-as-a-tumor-suppressor-in-ulcerative-colitis-associated-colorectal-neoplasia-through-regulation-of-focal-adhesion-signaling
#1
Joel Pekow, Alan L Hutchison, Katherine Meckel, Kymberly Harrington, Zifeng Deng, Nitya Talasila, David T Rubin, Stephen B Hanauer, Roger Hurst, Konstantin Umanskiy, Alessandro Fichera, John Hart, Aaron R Dinner, Marc Bissonnette
BACKGROUND: As mechanisms of neoplasia in patients with ulcerative colitis (UC) remain poorly understood, we sought to identify pathways of carcinogenesis in this high-risk population. METHODS: MicroRNA (miRNA) and mRNA expression was examined in nondysplastic rectosigmoid mucosa from UC patients with (n = 19) or without remote colon neoplasia (n = 23). We developed a method to identify miRNA-regulated pathways based on differentially expressed miRNAs and their putative mRNAs targets in the same samples...
June 9, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28475384/optimizing-pharmacologic-management-of-inflammatory-bowel-disease
#2
REVIEW
Shannon Chang, Stephen Hanauer
As our medical armamentarium for IBD continues to expand, it is essential that clinicians understand both optimizing and sequencing of individual and combination therapeutic approaches with available medications. Areas covered: This review summarizes dosing strategies and therapeutic drug monitoring for pharmacologic optimization in IBD. Aminosalicylates remain first-line therapies for mild-to-moderate UC but have limited evidence of efficacy in CD. Budesonide provides an alternative to aminosalicylates when targeted to appropriate sites in the distal small bowel and colon, as do conventional corticosteroids when applied rectally...
June 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28447072/a-randomized-trial-of-the-effects-of-the-no-carrageenan-diet-on-ulcerative-colitis-disease-activity
#3
Sumit Bhattacharyya, Theresa Shumard, Hui Xie, Amar Dodda, Krista A Varady, Leo Feferman, Allan G Halline, Jay L Goldstein, Stephen B Hanauer, Joanne K Tobacman
BACKGROUND: Carrageenan is a very common food additive in Western diets, but predictably causes inflammation in thousands of cell-based and animal experiments. OBJECTIVE: To assess the impact of carrageenan exposure on the interval to relapse in patients with ulcerative colitis in remission. METHODS: A randomized, double-blind, placebo-controlled, multicenter, clinical trial was conducted to assess if patients with ulcerative colitis in remission would have a longer interval to relapse if they followed a diet with no carrageenan...
March 31, 2017: Nutrition and Healthy Aging
https://www.readbyqxmd.com/read/28411871/targeting-interleukin-23-for-crohn-s-disease-finding-the-right-drug-for-the-right-patient
#4
Stephen B Hanauer
No abstract text is available yet for this article.
April 29, 2017: Lancet
https://www.readbyqxmd.com/read/28267049/the-influence-of-methotrexate-treatment-on-male-fertility-and-pregnancy-outcome-after-paternal-exposure
#5
Anne Grosen, Jens Kelsen, Christian Lodberg Hvas, Emanuelle Bellaguarda, Stephen B Hanauer
BACKGROUND: Inflammatory bowel disease incidence peaks during the reproductive years. Methotrexate (MTX) is frequently used for inflammatory bowel disease, but its use during pregnancy is contraindicated in women because of teratogenic effects. The aim of this review is to investigate the influence of MTX on male fertility and pregnancy outcomes after paternal MTX exposure. METHODS: A systematic literature search was performed by applying 2 focus areas, "methotrexate" and "male fertility or pregnancy outcome...
April 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28238954/histologic-normalization-occurs-in-ulcerative-colitis-and-is-associated-with-improved-clinical-outcomes
#6
Britt Christensen, Stephen B Hanauer, Jonathan Erlich, Olufemi Kassim, Peter R Gibson, Jerrold R Turner, John Hart, David T Rubin
BACKGROUND & AIMS: Mucosal healing, determined by histologic analysis, is a potential therapeutic target for patients with ulcerative colitis (UC). However, the histologic features of tissue normalization, as an outcome of treatment, have not been well described. We examined the prevalence and predictive values of normalization of the colonic mucosa, based on histologic analysis (histologic normalization) in patients with UC, and determined its association with risk of clinical relapse, compared with disease quiescence and mucosal healing...
February 24, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28164249/extrapolation-and-interchangeability-of-infliximab-and-adalimumab-in-inflammatory-bowel-disease
#7
REVIEW
Shannon Chang, Stephen Hanauer
Infliximab and adalimumab biosimilars have been approved by the FDA and European Medicines Agency and have already been introduced to the international market. Availability into the US market is imminent. Biosimilars are highly similar to the reference biologic product but should not be referred to as, nor equated with, generic medications as no two biosimilars can ever be identical. Regulatory pathways for biosimilar approval consider the totality of evidence for biosimilar approvals, but the preponderance of development relies on analytic and functional testing and allows extrapolation between indications to reduce the financial burden of completing comparative clinical trials for each indication...
March 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/27986473/issue-highlights
#8
Stephen B Hanauer
No abstract text is available yet for this article.
December 13, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27959607/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease
#9
RANDOMIZED CONTROLLED TRIAL
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao, Omoniyi J Adedokun, Bruce E Sands, Stephen B Hanauer, Severine Vermeire, Stephan Targan, Subrata Ghosh, Willem J de Villiers, Jean-Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce A Salzberg, Pierre Desreumaux, Scott D Lee, Edward V Loftus, Levinus A Dieleman, Seymour Katz, Paul Rutgeerts
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. METHODS: We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials...
November 17, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27825894/vitamin-d-levels-and-outcomes-in-inflammatory-bowel-disease-which-is-the-chicken-and-which-is-the-egg
#10
EDITORIAL
Stephen B Hanauer
No abstract text is available yet for this article.
February 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27780886/development-of-an-index-to-define-overall-disease-severity-in-ibd
#11
Corey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, Brian Feagan, Bruce Sands, Edward V Loftus, Remo Panaccione, Geert D'Haens, Charles N Bernstein, Richard Gearry, Siew C Ng, Gerassimos J Mantzaris, Balfour Sartor, Mark S Silverberg, Robert Riddell, Ioannis E Koutroubakis, Colm O'Morain, Peter L Lakatos, Dermot P B McGovern, Jonas Halfvarson, Walter Reinisch, Gerhard Rogler, Wolfgang Kruis, Curt Tysk, Stefan Schreiber, Silvio Danese, William Sandborn, Anne Griffiths, Bjorn Moum, Christoph Gasche, Francesco Pallone, Simon Travis, Julian Panes, Jean-Frederic Colombel, Stephen Hanauer, Laurent Peyrin-Biroulet
BACKGROUND AND AIM: Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC. METHODS: Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD...
October 25, 2016: Gut
https://www.readbyqxmd.com/read/27622191/primary-adenocarcinoma-of-an-ileostomy-in-crohn-s-disease
#12
Kevin Liu, Meena A Prasad, Amy Lo, Emanuelle Bellaguarda, Scott Strong, Stephen B Hanauer
Although Crohn's disease has been associated with an increased risk of small bowel adenocarcinoma, primary adenocarcinoma arising from an ileostomy is a complication that has been rarely documented in Crohn's disease. Chronic small bowel inflammation may lead to development of malignancy through the dysplasia-carcinoma sequence. We report a case of a 61-year-old woman with Crohn's ileocolitis diagnosed with a primary adenocarcinoma at the ileostomy with metastases to the liver 47 years after proctocolectomy, and review the literature...
July 2016: ACG Case Reports Journal
https://www.readbyqxmd.com/read/27585411/interpreting-registrational-clinical-trials-of-biological-therapies-in-adults-with-inflammatory-bowel-diseases
#13
Subrata Ghosh, William J Sandborn, Jean-Frederic Colombel, Brian G Feagan, Remo Panaccione, Stephen Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Severine Vermeire, Samantha Eichner, Bidan Huang, Anne M Robinson, Brandee Pappalardo
BACKGROUND: The use of biologics to treat inflammatory bowel disease is supported by robust randomized controlled trials in both ulcerative colitis and Crohn's disease. Nonetheless, an understanding of the principles of clinical trial design is necessary to extrapolate study findings to clinical practice. METHODS: We conducted a review of inflammatory bowel disease registrational clinical trials of biologics to determine how differences in trial design potentially influence results and interpretation...
November 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27400222/reinduction-with-certolizumab-pegol-in-patients-with-crohn-s-disease-experiencing-disease-exacerbation-7-year-data-from-the-precise-4-study
#14
Scott D Lee, David T Rubin, William J Sandborn, Charles Randall, Ziad Younes, Stefan Schreiber, David A Schwartz, Robert Burakoff, David Binion, Themos Dassopoulos, Razvan Arsenescu, Alexandra Gutierrez, Ellen Scherl, Cem Kayhan, Iram Hasan, Gordana Kosutic, Marshall Spearman, David Sen, Jason Coarse, Stephen Hanauer
BACKGROUND: Patients with Crohn's disease in whom tumor necrosis factor antagonist therapy fails have limited treatment options, and the benefit of reintroducing the same therapy remains unclear. Here, we report results from PRECiSE 4 (NCT00160706), an open-label extension study of certolizumab pegol in patients who withdrew from the placebo-controlled studies PRECiSE 1 or 2. METHODS: Patients eligible for PRECiSE 4 had Crohn's disease exacerbation on placebo or primary or secondary failure to certolizumab pegol in PRECiSE 1 or 2, and received 400 mg certolizumab pegol subcutaneously at weeks 0, 2, and 4 and every 4 weeks thereafter up to 360 weeks...
August 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27372735/aminosalicylates-for-induction-of-remission-or-response-in-crohn-s-disease
#15
REVIEW
Wee-Chian Lim, Yongjun Wang, John K MacDonald, Stephen Hanauer
BACKGROUND: Randomized trials investigating the efficacy of aminosalicylates for the treatment of mildly to moderately active Crohn's disease have yielded conflicting results. A systematic review was conducted to critically examine current available data on the efficacy of sulfasalazine and mesalamine for inducing remission or clinical response in these patients. OBJECTIVES: To evaluate the efficacy of aminosalicylates compared to placebo, corticosteroids, and other aminosalicylates (alone or in combination with corticosteroids) for the treatment of mildly to moderately active Crohn's disease...
July 3, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27318066/evaluation-of-a-proximity-card-authentication-system-for-health-care-settings
#16
Jacqueline Fontaine, Kai Zheng, Cosmas Van De Ven, Huiyang Li, James Hiner, Kathy Mitchell, Stephen Gendler, David A Hanauer
BACKGROUND: Multiple users access computer workstations in busy clinical settings, requiring many logins throughout the day as users switch from one computer to another. This can lead to workflow inefficiencies as well as security concerns resulting from users sharing login sessions to save time. Proximity cards and readers have the potential to improve efficiency and security by allowing users to access clinical workstations simply by bringing the card near the reader, without the need for manual entry of a username and password...
August 2016: International Journal of Medical Informatics
https://www.readbyqxmd.com/read/27281309/serum-25-hydroxyvitamin-d-concentration-is-inversely-associated-with-mucosal-inflammation-in-patients-with-ulcerative-colitis
#17
Katherine Meckel, Yan Chun Li, John Lim, Masha Kocherginsky, Chris Weber, Anas Almoghrabi, Xindi Chen, Austin Kaboff, Farhana Sadiq, Stephen B Hanauer, Russell D Cohen, John Kwon, David T Rubin, Ira Hanan, Atsushi Sakuraba, Eugene Yen, Marc Bissonnette, Joel Pekow
BACKGROUND: Vitamin D exerts anti-inflammatory actions both in vitro and in murine models of colitis. In previous studies, we demonstrated that vitamin D protects against the development of colitis by maintaining the integrity of the intestinal mucosal barrier. OBJECTIVE: We sought to evaluate whether deficient serum 25 hydroxyvitamin D [25(OH)D] concentrations are associated with increased mucosal inflammation, a loss of epithelial junctional proteins, and an increase in mucosal inflammatory cytokines in patients with ulcerative colitis (UC)...
July 2016: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/27144850/ozanimod-induction-and-maintenance-treatment-for-ulcerative-colitis
#18
RANDOMIZED CONTROLLED TRIAL
William J Sandborn, Brian G Feagan, Douglas C Wolf, Geert D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul A Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson
BACKGROUND: Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract. METHODS: We conducted a double-blind, placebo-controlled phase 2 trial of ozanimod in 197 adults with moderate-to-severe ulcerative colitis. Patients were randomly assigned, in a 1:1:1 ratio, to receive ozanimod at a dose of 0...
May 5, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27086002/integrating-adolescents-and-young-adults-into-adult-centered-care-for-ibd
#19
REVIEW
Itishree Trivedi, Jane L Holl, Stephen Hanauer, Laurie Keefer
Planned healthcare transition, initiated in pediatric care, is a gradual process aimed at fostering the adolescent patient's disease knowledge and skills with the ultimate objective of preparing patients and families for adult-centered care. The process is critical in inflammatory bowel diseases (IBD) where there is an increased risk of non-adherence, hospitalizations, and emergency department use as young adult patients graduate from pediatric to adult-centered care. While evidence for healthcare transition in IBD is mounting, important gaps remain in the understanding of this process from the perspective of the adult gastroenterologist...
May 2016: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/27084110/issue-highlights
#20
Stephen B Hanauer
No abstract text is available yet for this article.
June 2016: Clinical Gastroenterology and Hepatology
keyword
keyword
76474
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"